Ms. R., a 29-year-old woman recently diagnosed with Bipolar…

Ms. R., a 29-year-old woman recently diagnosed with Bipolar I Disorder, is started on divalproex sodium (Depakote) for mood stabilization. During medication education, she asks, “How does this medication actually work to stabilize my mood?”As her PMHNP, you explain that valproate’s mood-stabilizing effects are related to its actions on neuronal excitability and neurotransmitter regulation.Which of the following best describes the mechanism of action of valproate?

You are the Family PMHNP-BC caring for Ms. Trottier who is i…

You are the Family PMHNP-BC caring for Ms. Trottier who is in the office for a follow up appointment. Ms. Tottier has a medical history of epilepsy and hypertension.  In the prior visit, the client’s Effexor XR was increased to 150 mg daily for depressive symptoms. As the Family-PMHNP-BC for this patient, which of the following would you consider. Please choose the best option. 

A 27-year-old man with schizophrenia presents with persisten…

A 27-year-old man with schizophrenia presents with persistent social withdrawal, flat affect, anhedonia, avolition, and impaired executive functioning despite adequate control of hallucinations and delusions with antipsychotic therapy. He denies paranoia or auditory hallucinations but struggles to initiate activities and maintain employment.The PMHNP recognizes that these symptoms reflect dysfunction in a specific dopamine pathway, which is not effectively targeted by strong D2 receptor blockade and may worsen with high-potency antipsychotics.Which dopamine pathway is most closely associated with the negative symptoms of schizophrenia observed in this patient?

This test consists of: (1) a multiple-choice questions and t…

This test consists of: (1) a multiple-choice questions and true and false. Each question in the first section is a treu or false or a multiple-choice question with four answer choices. Read each question and answer choice carefully and choose the ONE best answer

A 28-year-old female presents to the clinic with a “paralyzi…

A 28-year-old female presents to the clinic with a “paralyzing” fear of public speaking that has recently begun to interfere with her career as a marketing executive. She describes episodes of heart racing, shortness of breath, and trembling whenever she is required to lead a meeting. She requests a “fast-acting pill” she can take only when she has a presentation. Upon further assessment, the PMHNP notes the patient also experiences generalized worry on most days, muscle tension, and significant avoidance of social gatherings.Which of the following represents the most appropriate pharmacological strategy for this patient, and what is the neurobiological rationale for the choice?